A point-in-time test restarts from zero every time, ends when the budget does, and goes stale in six months. A subscription accumulates evidence, tests only what changed, and gets deeper every release. That difference shows up in your submission, your invoice, and your ship date.
A vulnerability found during development is a development artifact you control.
The same vulnerability found in formal testing is a document a reviewer reads.
Continuous testing surfaces findings early, while they are cheap to fix and before they ever reach a formal report or quality document. You control the timeline because nothing external has started a clock.
By the time the submission test runs, the volume and severity of what remains has already been reduced. Fewer findings in the FDA submission, fewer in the reports your customers read.
Every early fix leaves an evidenced test case behind, so the reduction is demonstrable rather than asserted.
When testing keeps pace with the product, each release costs a fraction of a full engagement.
That is only possible if someone kept the evidence.
Traceable test cases plus a digital twin of coverage let you diff the release and zero in on what actually changed.
The rest carries hundreds of executed test cases and the evidence to defend them.
Incremental testing means a milestone test closes in under two days.
Continuous SBOM monitoring means the report is current whenever you need it.
Keeping pace means each test covers a delta, not a device. Findings land while the release is still open instead of after it shipped.
If nothing changed in the software since the last test and every new public CVE is already triaged, the report can be regenerated on demand. That outlasts the six-month shelf life a one-time consulting test carries.
Testing stops being the gate. The evidence is standing by before anyone asks for it.
A point-in-time test maxes out at two or three weeks and scratches the same surface every time.
Researchers and HDOs testing your product have no such constraint.
Consulting depth stops where the engagement stops. Repeat it annually and you re-cover the same familiar ground rather than reaching further in.
Independent researchers and high-profile health systems spend as long as they want on your product. That asymmetry is why third-party vulnerability reports land so hard.
Each release targets what has not been tested or was never a focus, so breadth and depth accumulate across months and years, at lower cost than any single engagement.
Long-term engagements track the posture of the product, so guidance stops being generic.
The fix is contextual, and so is the retest it forces.
Consulting guidance is high-level because the consultant does not know the product. ELTON ships the ELTON Fix: prescriptive remediation down to the code, delivered as a ticket or over ELTON MCP, ready for a developer.
Subscription testing plus CVE management makes fix optimization possible: find the change that knocks out the most highs and criticals at once, rather than patching them one at a time.
The twin knows the blast radius of a fix, so revalidation covers what actually moved. That is what takes patch deployment from months to days.
AI finds vulnerabilities in days. The output is large, and raw volume is a liability without somewhere to put it.
The platform is what turns that volume into verdicts.
Faster discovery means more findings per release. Each one still needs exploitability determined, a CVSS rating, and a correct classification before anyone can act.
A vulnerability in code that is unreachable from the outside-the-case attack surface is not today’s problem. It gets tracked and addressed in time, not escalated as a crisis.
A medical device under regulatory exposure should not carry more than a handful of directly exploitable vulnerabilities. Point-in-time tests call everything exploitable because they lack the system context to say otherwise.
Subscription models share the value of AI with the customer: more testing, better results, the same price. A point-in-time engagement has no reason to pass the savings on, and every reason to keep the turnaround long.
One subscription, every release, with the evidence accumulating behind you.